SML0150

Sigma-Aldrich

Tolcapone

≥98% (HPLC)

Sinónimos:
Ro 40-7592, 3,4-Dihydroxy-4′-methyl-5-nitrobenzophenone
Empirical Formula (Hill Notation):
C14H11NO5
Número de CAS:
Peso molecular:
273.24
MDL number:
PubChem Substance ID:
NACRES:
NA.77
En este momento no podemos mostrarle ni los precios ni la disponibilidad

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

yellow

solubility

DMSO: ≥15 mg/mL

originator

Roche

storage temp.

2-8°C

SMILES string

Cc1ccc(cc1)C(=O)c2cc(O)c(O)c(c2)N+(O-)=O

InChI

1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3

InChI key

MIQPIUSUKVNLNT-UHFFFAOYSA-N

Gene Information

human ... COMT(1312)

¿Está buscando productos similares? Visit Guía de comparación de productos

Application

Tolcapone may be used in COMT-mediated cell signaling studies.
Tolcapone has been used in methyltransferase assay in human embryonic kidney 293 cells.

Packaging

10, 50 mg in glass bottle

Biochem/physiol Actions

Inhibition of catechol-O-methyltransferase by tolcapone increases the half-life and bioavailabilty of levodopa. It therefore is an effective adjunctive therapy in patients with Parkinson′s disease with motor response fluctuations.
Tolcapone is an orally active catechol-O-methyltransferase (COMT) inhibitor. It inhibits both central and peripheral COMT. Tolcapone crosses the blood-brain barrier, and has been used for L-DOPA adjunct therapy in the treatment of Parkinson′s Disease.

Features and Benefits

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Environment

signalword

Warning

hcodes

pcodes

Hazard Codes

N

Risk Statement

50

Safety Statement

61

RIDADR

UN 3077 9 / PGIII

Flash Point F

Not applicable

Flash Point C

Not applicable

Saviana Di Giovanni et al.
The Journal of biological chemistry, 285(20), 14941-14954 (2010-02-13)
Parkinson disease (PD) is the second most common neurodegenerative disorder after Alzheimer disease (AD). There is considerable consensus that the increased production and/or aggregation of alpha-synuclein (alpha-syn) plays a central role in the pathogenesis of PD and related synucleinopathies. Current...
Jon E Grant et al.
The Journal of nervous and mental disease, 200(11), 996-998 (2012-11-06)
The course of pathological gambling (PG) in women has been described as having a later age of initiation but a shorter time to problematic gambling ("telescoped"). This study examined evidence for telescoping and its relationship with comorbidities. Seventy-one treatment-seeking individuals...
Seppo Kaakkola
International review of neurobiology, 95, 207-225 (2010-11-26)
Entacapone and tolcapone are reversible COMT inhibitors which have been approved for clinical use in patients with Parkinson disease (PD). Nebicapone is a third COMT inhibitor which has been studied in humans. COMT inhibitors are used in combination with levodopa...
Jinchun Sun et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 877(24), 2557-2565 (2009-07-21)
The process of drug metabolite identification is extremely important for drug efficacy, safety and pharmacokinetics. The traditional method usually involves using a drug with a radioactive labeled nuclei and/or isolating major drug metabolites by HPLC before applying MS and NMR...
Development of an HTRF assay for the detection and characterization of inhibitors of catechol-O-methyltransferase
Kimos M, et al.
Journal of Biomolecular Screening, 21, 490-495 (2016)

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.